@misc{10481/61486,
year = {2019},
month = {9},
url = {http://hdl.handle.net/10481/61486},
abstract = {Dyslipidemia and statin use have been associated with colorectal cancer (CRC), but prospective studies
have shown mixed results. We aimed to determine whether dyslipidemia is causally linked to CRC risk
using a Mendelian randomization approach and to explore the association of statins with CRC. A casecontrol
study was performed including 1336 CRC cases and 2744 controls (MCC-Spain). Subjects were
administered an epidemiological questionnaire and were genotyped with an array which included
polymorphisms associated with blood lipids levels, selected to avoid pleiotropy. Four genetic lipid
scores specific for triglycerides (TG), high density lipoprotein cholesterol (HDL), low density lipoprotein
cholesterol (LDL), or total cholesterol (TC) were created as the count of risk alleles. The genetic lipid
scores were not associated with CRC. The ORs per 10 risk alleles, were for TG 0.91 (95%CI: 0.72–1.16,
p = 0.44), for HDL 1.14 (95%CI: 0.95–1.37, p = 0.16), for LDL 0.97 (95%CI: 0.81–1.16, p = 0.73), and for
TC 0.98 (95%CI: 0.84–1.17, p = 0.88). The LDL and TC genetic risk scores were associated with statin
use, but not the HDL or TG. Statin use, overall, was a non-significant protective factor for CRC (OR
0.84; 95%CI: 0.70–1.01, p = 0.060), but lipophilic statins were associated with a CRC risk reduction (OR 0.78; 95%CI 0.66–0.96, p = 0.018). Using the Mendelian randomization approach, our study does not
support the hypothesis that lipid levels are associated with the risk of CRC. This study does not rule out,
however, a possible protective effect of statins in CRC by a mechanism unrelated to lipid levels.},
organization = {This work was supported by the ‘Acción Transversal del Cancer’, approved by the Spanish Ministry Council
on the 11th October 2007, by the Instituto de Salud Carlos III, co-founded by FEDER funds –‘a way to build
Europe’ [grants PI08/1770, PI08/0533, PI08/1359, PI09/00773, PI09/01286, PI09/01903, PI09/02078, PI09/01662,
PI11/01403, PI11/01889, PI11/00226, PI11/01810, PI11/02213, PI12/00488, PI12/00265, PI12/01270, PI12/00715,
PI12/00150, PI14/01219, PI14/00613, PI17/00092 and PI15/00069]. Support was also provided by the Fundación
Marqués de Valdecilla (grant API 10/09]; the Junta de Castilla y León [grant LE22A10-2]; the Consejería de Salud of the Junta de Andalucía [2009-S0143]; the Conselleria de Sanitat of the Generalitat Valenciana [grant
AP 061/10]; the Recercaixa [grant 2010ACUP 00310]; the Regional Government of the Basque Country; the
Consejería de Sanidad de la Región de Murcia; European Commission grants FOOD-CT-2006-036224-HIWATE;
the Spanish Association Against Cancer (AECC) Scientific Foundation; the Catalan Government DURSI [grants
2017SGR723 and 2014SGR850]; the Fundación Caja de Ahorros de Asturias; the University of Oviedo; Societat
Catalana de Digestologia; and COST action CA17118 Transcoloncan.},
publisher = {Springer Nature},
title = {Mendelian randomization analysis rules out disylipidaemia as colorectal cancer cause},
doi = {10.1038/s41598-019-49880-w},
author = {Ibáñez Sanz, Gemma and Jiménez Moleón, José Juan},
}